Several biomarkers, ranging from tumor mutation burden and PD-L1 expression to microsatellite instability and Epstein–Barr virus infection status, have been proposed as potential indicators for identifying susceptibility to PD-1/PD-L1 inhibitors in gastric cancer (7, 8). Here, PDCD1 is linked to neoplasm.